Amneal Pharmaceuticals (NASDAQ:AMRX) Downgraded by Wall Street Zen to "Buy"

Key Points

• Wall Street Zen downgraded Amneal Pharmaceuticals from “strong buy” to “buy.”
• Analyst sentiment remains positive overall: eight analysts rate the stock a Buy and two a Hold, with a “Moderate Buy” consensus and an average price target of $23.
• Amneal reported quarterly EPS of $0.26, beating the $0.23 consensus estimate, on revenue of $862.68 million.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research report issued on Saturday, Wall Street Zen reports.

Other research analysts also recently issued research reports about the company. The Goldman Sachs Group restated a "buy" rating and issued a $24.00 target price on shares of Amneal Pharmaceuticals in a research note on Thursday, October 29th. Weiss Ratings lowered Amneal Pharmaceuticals from a "buy (b)" rating to a "hold (c+)" rating in a report on Tuesday. Zacks Research upgraded Amneal Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Monday, October 26th. Barclays upped their price target on Amneal Pharmaceuticals from $16.00 to $20.00 and gave the company an "overweight" rating in a research report on Thursday, September 17th. Finally, Leerink Partners increased their price target on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock an "outperform" rating in a report on Thursday, November 5th. Eight equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $23.00.

Amneal Pharmaceuticals Stock Down 1.5%

Amneal Pharmaceuticals stock opened at $21.38 on Friday. Amneal Pharmaceuticals has a 1-year low of $11.39 and a 1-year high of $22.07. The firm has a market capitalization of $6.83 billion, a price-to-earnings ratio of 22.84, a P/E/G ratio of 2.47 and a beta of 1.24. The company has a current ratio of 1.87, a quick ratio of 1.24 and a debt-to-equity ratio of 5.61. The firm has a 50 day simple moving average of $19.71 and a 200 day simple moving average of $16.11.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its earnings results on Tuesday, November 3rd. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.03. Amneal Pharmaceuticals had a return on equity of 283.50% and a net margin of 4.17%. The firm had revenue of $862.68 million for the quarter. On average, analysts predict that Amneal Pharmaceuticals will post 0.98 earnings per share for the current year.

Institutional Trading of Amneal Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC boosted its holdings in Amneal Pharmaceuticals by 54.9% in the third quarter. GAMMA Investing LLC now owns 1,605 shares of the company's stock valued at $32,000 after acquiring an additional 569 shares in the last quarter. Fortitude Family Office LLC raised its position in shares of Amneal Pharmaceuticals by 100.9% in the 3rd quarter. Fortitude Family Office LLC now owns 1,607 shares of the company's stock worth $32,000 after acquiring an additional 807 shares in the last quarter. Sterling Capital Management LLC grew its stake in Amneal Pharmaceuticals by 30.3% in the third quarter. Sterling Capital Management LLC now owns 3,549 shares of the company's stock worth $71,000 after purchasing an additional 825 shares during the period. Arizona State Retirement System raised its holdings in Amneal Pharmaceuticals by 1.9% in the second quarter. Arizona State Retirement System now owns 44,011 shares of the company's stock worth $762,000 after purchasing an additional 837 shares in the last quarter. Finally, Yousif Capital Management LLC lifted its position in Amneal Pharmaceuticals by 2.9% during the third quarter. Yousif Capital Management LLC now owns 42,839 shares of the company's stock valued at $863,000 after buying an additional 1,197 shares during the period. Institutional investors own 31.82% of the company's stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals is a U.S.-based pharmaceutical company that develops, manufactures and markets generic and specialty medicines. Its products include a broad range of generic drugs, including complex formulations and injectable medicines, as well as branded therapies in areas such as neurology and endocrinology. The company also operates AvKARE, which distributes pharmaceuticals and medical products to government, institutional and commercial customers. Amneal serves customers in the United States and in international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.